The Effectiveness of Moxibustion: An Overview During 10 Years by Kim, Song-Yi et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 306515, 19 pages
doi:10.1093/ecam/nep163
Review Article
The Effectivenessof Moxibustion: An Overview During10 Years
Song-YiKim,1,2 Younbyoung Chae,1,2 SeungMinLee,1 Hyejung Lee,1,2 and Hi-Joon Park1,2
1Department of Meridian and Acupoint, College of Korean Medicine, Kyung Hee University, 1 Hoegidong, Dongdaemungu,
Seoul, 130-701, Republic of Korea
2Acupuncture and Meridian Science Research Center (AMSRC), Kyung Hee University, 1 Hoegidong, Dongdaemungu,
Seoul, 130-701, Republic of Korea
Correspondence should be addressed to Hi-Joon Park, acuﬁnd@khu.ac.kr
Received 21 May 2009; Accepted 30 August 2009
Copyright © 2011 Song-Yi Kim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Moxibustion has been used to treat various types of disease. However, there is still insuﬃcient evidence regarding its eﬀectiveness.
This study was performed to summarize and evaluate the eﬀectiveness of moxibustion. A search was performed for all randomized
controlled trials in PubMed between January 1998 and July 2008 with no language restriction. The results yielded 47 trials in
which six moxibustion types were applied to 36 diseases ranging from breech presentation to digestive disorders. Moxibustion
was compared to three types of control group: general care, Oriental medical therapies or waiting list. Moxibustion was superior
to the control in 14 out of 54 control groups in 46 studies. There were no signiﬁcant diﬀerences among groups in 7 studies, and
the outcome direction was not determined in 33 studies. Seven studies were included in a meta-analysis. Moxibustion was more
eﬀective than medication in two ulcerative colitis studies (relative risk (95% CI), 2.20 (1.37, 3.52), P = .001, I 2 = 0%). Overall,
our results did not support the eﬀectiveness of moxibustion in speciﬁc diseases due to the limited number and low quality of the
studies and inadequate use of controls. In order to provide appropriate evidence regarding the eﬀectiveness of moxibustion, more
rigorous clinical trials using appropriate controls are warranted.
1.Introduction
Acupuncture and moxibustion, representative therapeutic
modalities in traditional medicine for more than 2500 years
[1], are still being used in primary healthcare systems in
East Asia [2]. Traditional treatments including acupuncture-
related therapies (acupuncture, moxibustion and acupres-
sure) and herbal remedies account for 40% of all healthcares
in China [3]. In Korea, it was reported that 67% of Korean
medical doctors use moxibustion as a therapeutic tool alone
or in addition to their clinical practice [4, 5]. Acupunc-
ture and moxibustion are similar regarding stimulation
of acupuncture points on the Meridian [6]. Moxibustion
uses thermal and chemical stimulants by burning herbal
materials, including mugwort (Artemisia vulgaris,m o x a ) ,
whereas acupuncture uses physical stimulation via insertion
of needles [7]. The therapeutic components of moxibustion
are assumed that the combination of heat (burning pain and
heat stress), tar (extract), aroma (fume) and psychological
stress [8]. Among them, heat stimulation and chemical
action of ignited moxa is the most important variable
for moxibustion [9]. As the method of acupuncture and
moxibustion is diﬀerent, there are functional distinctions
between them. Acupuncture generally makes body release
heat, or eliminates pathogen while moxibustion mainly
makes body warm and recruits healthy qi [10]. Therefore,
acupuncture and moxibustion are used to cover diﬀerent
conditions, while they share some common applications at
the same time [11]. Recently, pre-clinical studies suggested
that moxibustion boosts the immune system [8, 12]a n d
enhances physiological functions [13]. In addition, accu-
mulating clinical data support the use of moxibustion [14–
19]. However, there have been few systematic reviews of
the application of moxibustion, except in cases of breech
presentation [20–22], and evidence regarding the eﬃcacy of
moxibustion is very limited.
The aims of this review are to summarize the present
status of clinical research on moxibustion and to evaluate the
evidence for the eﬀectiveness of moxibustion.
2. Methods
2.1.SearchStrategiesandSelectionofStudies.Asearchwasper -
formedinPubMed(http://www.ncbi.nlm.nih.gov/pubmed/),
which oﬀers better indexing and more search features [23],
for the period spanning January 1998 to July 2008, with no2 Evidence-Based Complementary and Alternative Medicine
language restriction. The literature search was performed
using the key words “moxibustion” and “moxa”, and refe-
rence lists from the original articles and reviews were
examined for additional studies.
Studies fulﬁlling the following criteria were included: (i)
studies presenting the results of a randomized controlled
trial (RCT); and (ii) studies using moxibustion in the
intervention group. Studies in which moxibustion were
administered to both the intervention and control groups
were excluded. Studies using warm needles (i.e., examining
not the eﬃcacy of moxibustion itself, but its eﬀects in
addition to acupuncture) were also excluded. No limitations
were applied to the type of disease, outcome measure or
control group.
2.2. Data Extraction and Quality Assessment. The data
were extracted systematically in a pre-deﬁned, standardized
manner according to the study designs, number of subjects,
intervention, and control groups. Selection, extraction, and
quality assessment were performed independently by two
reviewers (Kim SY and Lee S). Discrepancies were resolved
by discussion between reviewers. A modiﬁed Jadad scale was
used to assess the methodological quality of the included
studies [24, 25]. This scale assesses randomization (if the
study was randomized, add 1 point; add an additional
point for appropriate randomization and deduct 1 point for
inappropriate randomization), patient and assessor blinding
(add 1 point each), and reports of dropouts and withdrawals
(add 1 point). The Jadad score ranges from 0 to 5 points. We
considered trials with ≥3 points to be of high quality.
2.3. Data Analysis. As all available studies related to the
eﬃcacy of moxibustion were included, the diseases for
this review were very heterogeneous. Therefore, we catego-
rized each disease according to the International Statistical
Classiﬁcation of Diseases and Related Health Problems,
10th Revision (ICD-10). All the outcomes included were
reviewed. To interpret the results eﬃciently and brieﬂy, with
compensation for heterogeneity, two alternative analyses
were used: the relative risk (RR) and classiﬁcation score. For
studies providing eﬀe c t i v er a t e sa sa no u t c o m em e a s u r e ,t h e
RRand95%conﬁdenceinterval(CI)werecalculated,andre-
analyzed using the χ2 test. “Clinically cured” and “markedly
eﬀective” were included for success. When the RR could not
be calculated, the appropriateness of outcomes related to the
corresponding disease was discussed with experts from the
Kyung Hee University Oriental Medical Hospital, followed
by review of the statistical methods. For the classiﬁcation
score, the outcomes were deﬁned as follows: (i) positive
when moxibustion was signiﬁcantly more eﬀective than the
control group (P); (ii) neutral when moxibustion was not
signiﬁcantly diﬀerent from the control group (NEU); (iii)
negative when the control group was signiﬁcantly more
eﬀective than moxibustion (N); and (iv) not determined
(ND) when the outcome measure was not appropriate for
disease, the control was not adequate to prove the evidence
of moxibustion, or the results were not clear. P and N were
given only when the results of both author and reviewer were
the same. If there was disagreement between authors and
reviewers, the study was classiﬁed as ND. Meta-analyses were
performed when the provided data were appropriate. The
I2 statistic describes the percentage of the total variability
in study estimates that is due to heterogeneity rather than
chance alone. The mean eﬀect size was calculated using
ar a n d o me ﬀects model, as we assumed that each study
assessed diﬀerent moxibustion treatments and thus diﬀerent
eﬀects. Sensitivity analysis was performed using the χ2 test to
examine the statistical signiﬁcance of associations between
trial methodological quality, country, languages, type of
intervention, comparative control group and trial outcome
based on classiﬁcation score. SPSS software (Version 13.0)
and Review Manager (RevMan 5.0; The Nordic Cochrane
Centre, Copenhagen) were used for statistical analyses, and
P<. 05 was taken to indicate signiﬁcance.
3. Results
3.1. Study Characteristics. A total of 737 potentially relevant
studies were identiﬁed and screened for retrieval. Forty eight
of these studies [14, 16, 17, 26–70] fulﬁlled the inclusion
criteria for this review (Figure 1) and are presented in
Table 1. Two papers by Liu et al. [27, 28] on malignant
tumors described the same populations and were considered
asonestudy.Therefore,weincluded47studiesinthisreview.
In total, moxibustion was compared to 54 control groups
in 47 studies where seven of these were three-armed studies
[17, 31, 32, 34, 40, 49, 56].
MostofthestudieswereconductedinChina(41studies),
three in Italy [14, 16, 17], and three in Korea [40, 61, 64].
Thirty-three papers were written in Chinese, and the rest
were in English.
3.2. Participants and Conditions. A total of 4434 patients
(2274 in the moxibustion group, 2160 in the control group)
participated in the studies, and the data from 4360 patients
(2239 in the moxibustion group, 2121 in the control group)
were analyzed. The average number of subjects in each group
rangedfrom5to130inthemoxibustiongroups(mean ±SD,
46.4 ± 28.6) and 5 to 130 in the controls (41.5 ± 25.6). The
median sample sizes per group (moxibustion and control)
were 38 and 34, respectively.
The ICD-10 was used to categorize disorders treated
with moxibustion. Thirty-six types of disease were included
within 13 subcategories of the ICD-10. The most frequently
examined disorders were diseases of the musculoskeletal
system and connective tissue (Chapter XIII, n = 7), the
genitourinary system (Chapter XIV, n = 7), pregnancy,
childbirth and the puerperium (Chapter XV, n = 7), and
the digestive system (Chapter XI, n = 6). Others included
diseases of the nervous system (Chapter VI, n = 4), the
respiratorysystem(ChapterX,n = 4),endocrine,nutritional
and metabolic diseases (Chapter IV, n = 3), neoplasms
(Chapter II, n = 2), diseases of the circulatory system
(Chapter IX, n = 2), the skin and subcutaneous tissues
(ChapterXII,n = 2),certaininfectiousandparasiticdiseases
(Chapter I, n = 1), the blood and blood-forming organs
and certain disorders involving the immune system (Chapter
III, n = 1), and the eye, adnexa, ear and mastoid processEvidence-Based Complementary and Alternative Medicine 3
Potentially relevant studies identiﬁed and screened for retrieval (n = 737)
Excluded on the basis of title and abstract (n = 416)
Studies included in meta-analysis (n = 7) and second analysis (n = 39)
Studies excluded (n = 273)
Not focus on moxibustion (about acupuncture/CAM)
Potentially appropriate RCTs
to be included in this
systematic review (n = 48∗)
About moxibustion plus another intervention (n = 112) (a)
Study design: case series (physical) (n = 1) (iv)
RCT or CCT but moxibustion used all group (n = 2) (a)
About moxibustion (n = 72) (b)
Study design: case series (moxibustion plus another
intervention) (n = 15)
(c)
Study design: case series (moxibustion) (n = 9) (d)
Study design: CCTs (moxibustion) (n = 3) (e)
Warm needling therapy (n = 25) (f)
Animal study (n = 14) (i)
Study design: review or literature research or protocol (ii)
Study design: case series (physical) (n = 1) (iii)
Animal study (n = 32) (i)
Device of moxibustion study (n = 17) (ii)
Study design: review or literature research or protocol
study (n = 22)
(iii)
RCT or CCT but treatment group was treated
moxibustion plus another intervention (n = 35)
(b)
(1) No clinical study (n = 184)
(2) Clinical studies, but studies are inappropriate as
following reason (n = 89)
(n = 97) study
Figure 1: Flow diagram of literature search. ∗Two RCTs [27, 28] were considered as one study as they used the same population.
(Chapters VII and VIII, n = 1). Among the 36 individual
conditions included in these studies, the most frequently
researched conditions were breech presentation (n = 7;
[14, 16, 17, 67–70]), and tumors (n = 3; [27–29]).
3.3.MoxibustionInterventionsandControlGroups. Thereare
various methods of moxibustion treatment, including direct
and indirect treatment with moxa cones, moxa sticks, moxa
rolls with herbs, and natural moxibustion. We classiﬁed the
treatments based on the World Health Organization (WHO)
internationalstandardterminologiesontraditionalmedicine
[6]. Direct and indirect moxibustion using a moxa cone was
the most commonly used method in the studies included in
this review. Direct moxibustion, in which an ignited moxa
cone is applied directly to the skin surface at the acupuncture
point [6], was used in seven studies [26, 39, 42, 48, 59,
61, 66]. In addition, indirect moxibustion, performed by
placing some insulating material (ginger, salt, garlic, etc.,
accordingtosymptoms)betweenthemoxaconeandtheskin
[6], was used in 19 studies [29, 30, 32, 36, 40, 45, 47, 49–
52, 54, 56, 58, 60, 62–65]. Moxa stick moxibustion involves
the use of ignited moxa sticks named according to the type of
stimulation method used (gentle, circling, pecking sparrow,
and suspended moxibustion) [6] and was used in 19 studies
[14, 16, 17, 27, 28, 31, 34, 35, 37, 41, 44, 46, 53, 55, 57, 67–
70]. Moxa rolls with herbs (Taiyi moxa stick) were used in
one study [33]. In addition, natural moxibustion, known
as vesiculation moxibustion, in which irritants are applied
at the acupuncture points to produce blistering and local
congestion [6], was used in one study [43]. One study
[38] employed multiple moxibustion techniques. The most
frequently used acupuncture point was ST36 (n = 13),4 Evidence-Based Complementary and Alternative Medicine
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followed by CV8 (n = 11), BL23 (n = 10), BL20 (n = 8), CV4
(n = 7), GV14 (n = 7), BL67 (n = 7), SP6 (n = 5), BL13 (n =
4), and BL18 (n = 4). Participants received treatments 4 to 90
times (median, 20).
Threetypesofcontrolgroupwereincludedinthestudies:
(i) general care (n = 11), such as Western medication (n = 8),
vitamin therapy (n = 1), injection of transfer factor (n = 1),
and posture care (n = 1); (ii) oriental medical therapy (n =
20), such as acupuncture (n = 9), herbal medicine (n = 7), or
combinedtraditionaltherapies(n=4);and(iii)notreatment
(n = 23), such as being placed on a waiting list (n = 2) or no
additionaltreatmentwiththeco-intervention(n=21).There
were no studies in which treatment eﬀects were compared
to a sham-control with indistinguishable appearance and no
physiological eﬀect.
3.4. Methodological Quality. Total 47 RCTs were included
in this review. The scores for the methodological quality
of the RCTs varied from 0 to 4. Most suﬀered from poor
methodological quality. None of the RCTs were given the
maximum of 5 points on the modiﬁed Jadad scale. Seven
[16, 30, 35, 53, 54, 60, 61] of eight studies with more than
3 points for quality were published after 2005. Seven trials
used a single blind method (patient or assessor), and there
were no double (patient and assessor) blind studies included
in the review. Only 31 RCTs described the method of
randomizationandnineusedaninappropriatemethod,such
as allocation according to treatment order. Power analysis
was reported in only one study [16].
3.5. Outcomes. Eighty-three percent of the studies included
in this review reported an eﬀe c t i v er a t e( 3 9o f4 7s t u d i e s ) ,
and these were included in the secondary analysis comparing
RRs among groups (Table 1). The classiﬁcation score for the
overall eﬀects was decided considering both the authors’ and
the reviewers’ interpretations. According to the classiﬁcation
score, moxibustion was superior to the control in 14 of 54
controlgroup in 47 studies (26%). There were no statistically
signiﬁcant diﬀerences between groups in 7 studies (13%).
The outcome direction was not determined in 33 studies
(61%) for the following four reasons: (i) inappropriate
outcome measures for the indicated disorder; (ii) details of
the outcome measures were not described; (iii) the results
were too complex to be determined; or (iv) inappropriate
control to estimate the eﬀectiveness. Among the 8 studies
classiﬁed as high quality on the Jadad scale [14, 16, 30, 35,
53, 54, 60, 61], three studies could not be determined the
direction of outcome, due to inappropriate control. Only ﬁve
studieswereestimatedtheirclassiﬁcationscoreastwostudies
were positive, and three neutral. In details of high quality
studies, indirect moxibustion for 20 days did not improve
thesymptomsofosteoarthritiscomparedtomedicationafter
treatment, but not in 2 months later, follow up point [54].
Patients for end stage renal failure in hemodialysis were
measured by Kidney Disease Quality of life, but moxibustion
didn’thaveadditionaleﬀectwithmedication[60].Onestudy
[61] for post-stroke urinary symptoms showed additional
eﬀect with oriental medical therapy as co-intervention, and
this result was not contradictory to other low quality study
[62]. Other two high qulity studies [14, 16] for breech
presentation were attempted to polling, but not suitable as
heterogeneity.
In detail, 10 days of direct moxibustion generated
additional therapeutic eﬀects to acupuncture in cases of
herpes zoster [26] (RR (95% CIs), 1.67 (1.09–2.55), P =
.016). Moxibustion showed no additional eﬀects when used
in conjunction with chemotherapy or radiotherapy in mid-
to late-stage malignant tumors [27, 28] or nasopharyngeal
carcinoma [29]. Biweekly indirect moxibustion for 2 months
had an anti-aging eﬀect compared to vitamin E (9.33
(1.33, 65.49), P = .002) [32]. For hyperlipidemia [33], Taiyi
moxibustion for 3 months improved the patient response to
diet therapy in terms of cholesterol, triglyceride, and high-
density lipoprotein (HDL) levels. In Parkinson’s disease, 30
coursesofindirectmoxibustionimprovedtheeﬀectivenessof
medication based on the Uniﬁed Parkinson’s Disease Rating
Scale score (2.33 (1.04–5.21), P = .034) [36]. Stick moxi-
bustion for 1 month did not improve the eﬀects of a mixed
therapy (electroacupuncture, medication, and vitamins) in
facial paralysis [37], and 20 courses of stick moxibustion
were not superior to medication in the treatment of diabetic
peripheral neuropathy [34]. Direct moxibustion for 20
days provided additional improvement in the treatment
of ischemic apoplexy, as determined by clinical symptoms
and changes in transcranial Doppler (TCD) ﬁndings [39].
For allergic rhinitis and infantile repeated respiratory tract
infection, moxa stick application for 10 days or 1 month
was more eﬀective than medication (2.09 (1.12–3.90), P
= .025) [41] or intramuscular injection of transfer factor
(1.85 (1.22–2.80), P = .002) [44]. Moxibustion for 6 days
was superior to medication in infantile autumn diarrhea
(2.25 (1.60–3.17), P < .001) [45]. In patients with chronic
atrophic gastritis, moxibustion did not show an additional
eﬀect to acupuncture [46]. For ankylosing spondylitis [56],
rheumatoid arthritis [57] and cervical spondylosis [59],
moxibustion did not show additional beneﬁts.
Only seven studies were performed for statistical pooling
(Figure 2). Indirect moxibustion for 1 or 3 months was more
eﬀective than medication in two ulcerative colitis studies
(2.20 (1.37, 3.52), P = .001, I2 = 0%, P for heterogeneity
= .55) (Figure 2(a);[ 47, 50]). Moxa stick treatment for 1–2
weeksdidnotshowaeﬀectonbreechpresentationcompared
to no treatment control (1.19 (0.88, 1.60), P = .26, I2 = 40%,
P for heterogeneity = .20) in two studies (Figure 2(b); 14,16).
Moxa stick had additional eﬀect to the posture care (1.51
(1.10, 2.08), P = .01), although marked heterogeneity was
observed in this model (I2 = 86%, P for heterogeneity =
.0007, Figure 2(c);[ 68–70]).
The direction of study outcome (positive, neutral, not
determined, or negative) was not signiﬁcantly associated
with intervention type (moxa cone versus moxa stick versus
others, χ2 = 1.835, df = 4, P = .895), country of origin (East
Asia versus others, χ2 = .572, df = 2, P = .758), or language
(English versus other language, χ2 = 2.573, df = 2, P = .392).
Incaseoftheassociationbetweendirectionofstudyoutcome
and study quality (high versus low, as assessed using the
modiﬁed Jadad scale) seems to be near to P < .05 (χ2 = 5.222,
df = 2, P = .084), This may be caused by biased results thatEvidence-Based Complementary and Alternative Medicine 15
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Figure 2: Forest plot of moxibustion compared to control. (a) Moxibustion compared with medication in ulcerative colitis [46, 49]. (b)
Moxibustion compared with waiting-list control in breech presentation [14, 16]. (c) Moxibustion plus postual care compared with postual
care only in breech presentation [68–70].
studies of low quality show a tendency of ND or positive.
There was signiﬁcant association between the direction of
study outcome and control type (general care versus oriental
medical therapy control versus no additional treatment
with or without co-intervention, χ2 = 21.209, df = 4, P <
.001). It might be caused by inappropriate control, such
as oriental medical therapy. Moxibustion studies compared
to oriental medical therapy were assessed as ND. When
sensitivity analysis were performed excluding “ND”, the
direction of study outcome (positive, neutral, or negative)
was not signiﬁcantly associated with control group (general
care versus no additional treatment with or without co-
intervention, χ2 = .936, df = 2, P = .713).
3.6. Adverse Eﬀects. Only 12 studies [14, 16, 29, 30, 51, 52,
55, 57, 61, 62, 67, 68] commented on adverse events. Seven
studies [14, 51, 52, 55, 61, 67, 68] reported no adverse event
associated with moxibustion during the treatment period.
Patients participating in a rheumatoid arthritis study [57]
showed a slight and reversible increase in aminotransferase
levels (3 of 30 cases) and a slight reduction in leukocyte
count (two cases) after treatment with moxa sticks, whereas
those in the control group (treatment with methotrexate
and NSAIDs) had no appetite (nine cases), abnormal taste
(nine cases), nausea (eight cases), increased aminotrans-
ferase levels (six cases) and thrombocytopenia (ﬁve cases).
Liu et al. [62] reported slight burning and blistering in
two patients treated with indirect moxibustion for post-
stroke urinary tract symptoms. The two studies in which
moxibustion was applied to nasopharyngeal carcinoma [29]
and chemotherapy-induced leukopenia [30] also reported
toxic side eﬀects, but these were induced by radiotherapy
or chemotherapy, rather than moxibustion. In the study on
breech presentation, Cardini and weixin [14]r e p o r t e dn o
adverse event associated with moxibustion, and the numbers
of cases of premature rupture of the membranes (PROM)16 Evidence-Based Complementary and Alternative Medicine
and preterm delivery were less in the moxibustion group
compared to the waiting list control (4 cases versus 12 cases
ofPROMandtwocasesversusthreecasesofpretermdelivery
among 130 subjects, resp.) [14]. However, in another study
performed by the same group [16], two cases of preterm
deliverypossiblyduetoPROMandonecaseofbleedingwere
noted in association with moxibustion, whereas one case of
preterm delivery occurred in the waiting list control group.
In this study, moxibustion was associated with complaints
of unpleasantness and physical disturbances due to the odor
(42%), throat problems (22%), and abdominal pain because
of contractions (17%). Twenty-two percent of participants
temporarilyordeﬁnitivelyinterruptedthetreatmentbecause
of these symptoms. Peng’s study [67] for breech presentation
reported ﬁve cases of abdominal pain in control group.
4. Discussion
Although many studies have provided encouraging results
regarding the use of moxibustion in various disorders,
deﬁnitive conclusions cannot be drawn from the evidence
presented in this review. The use of moxibustion has been
studied in a wide range of diseases, from neoplasm to
pain, but we cannot properly evaluate the eﬀectiveness of
moxibustion in each disease due to the limited number of
corresponding studies. In addition, the overall quality of
these studies was low, and the use of controls was inap-
propriate. Nevertheless, meta-analysis suggested beneﬁcial
eﬀect that moxibustion appeared to be more eﬀective than
medication in ulcerative colitis. In breech presentation, there
isstrongheterogeneityexist,thustheresultsareinconclusive.
There have been three relevant systematic reviews on this
topic, however, the results are not directly comparable
because two were not focused on the moxibustion as an
intervention [21, 22], and one missed the relevant studies
included in our review [20].
Among the 36 individual conditions included in these
studies,themostfrequentlystudiedwerebreechpresentation
(n = 7; [14, 16, 17, 67–70]), and tumors (n = 3; 27–29).
As only one or two studies covered each disease, deﬁnitive
conclusions cannot be drawn.
We found that the quality of studies regarding moxi-
bustion was unsatisfactory. Thirty-nine of 47 studies (83%)
received scores of less than 3 on a modiﬁed Jadad scale. In
most studies, the details of the moxibustion procedure used
were not fully described. Methods regarding randomization
were unclear and power analysis was seldom reported.
Concealment of allocation and blinding methods were
not clearly described, and details regarding drop-out and
withdrawal rates were often insuﬃcient. Even the trials that
scored as high quality on the modiﬁed Jadad scale were not
devoid of ﬂaws; for example, none of the studies attempted
patient blinding and only one study reported power analysis;
several studies that had been expressed as positive in their
original papers were re-classiﬁed as ND because the outcome
measures were not appropriate either for the disease or the
results were contradictory; seventy-four percent of studies
did not report adverse events related to intervention. Despite
these shortcomings, we found that methodological quality
has improved recently, and seven of the eight high-quality
studies were published after 2005.
All of the studies used inappropriate controls, which
makes evaluation diﬃcult because controls in RCTs provide
important insight into the eﬀectiveness of the treatment
and help to eliminate factors that may otherwise skew the
results [71]. Furthermore, it is extremely diﬃcult to compare
each other and estimate their eﬀectiveness because of the
inappropriateness in the quality and control. In our analysis,
20 studies, which had been compared to oriental medical
therapy, were re-classiﬁed as ND because the controls
were not appropriate to estimate eﬀectiveness. The issue
of appropriate control methods for moxibustion has not
drawn a great deal of attention. Since many components,
such as heat, fumes, and moxa extract [8], may contribute
to the therapeutic eﬀect, developing appropriate controls
for moxibustion is not easy tasks. Two types of sham
moxibustion designed to isolate heat [72, 73]h a v eb e e n
introduced. However, it is not obvious whether subjects were
really blinded because the thermal intensity was diﬀerent.
Therefore, there is a need for a more appropriate sham
moxibustion method for use as a control.
Among the 12 RCTs that reported adverse events, none
reported serious adverse events. There were complaints
related to unpleasantness and physical disturbances due
to the odor [16]. Blistering and slight burning were also
reported in one studies [62]. Because moxibustion involves
thermal stimulation of the skin over a prolonged period,
it is important that only experienced and well-trained
practitioners provide this therapy [62]. In addition, for
widespread adoption of moxibustion, it will be necessary to
develop an odor-free device for its application.
This review had several limitations. Although we made
eﬀorts to retrieve all relevant RCTs, some studies in other
databases may have been missed. However, it is reported that
Pubmed oﬀers better indexing and more search features, and
there is overall a relatively high degree of overlap between
Medline and EMBASE and CENTRAL [23, 74]. Further
limitations include the paucity and the overall insuﬃcient
methodological quality of the primary data. As the quality
of clinical trials and reporting methodologies included in
this review was generally weak, further high-quality trials
are needed to assess the eﬀectiveness of moxibustion in
treating several diseases. In this regard, future trials should
adhere to rigorous trial designs that are suitable for the
research questions. To improve the research quality, future
researchersshouldfollowtheguidelinesforreportingclinical
trials, such as the Consolidated Standards of Reporting Trials
(CONSORT) statement. We suggest that speciﬁc guidelines
for the reporting of moxibustion trials, similar to the
Reporting Interventions in Controlled Trials of Acupuncture
(STRICTA) [75], should be developed and followed by
researchers.
In conclusion, even though our results for the eﬀective-
ness of moxibustion are not conclusive due to the hetero-
geneity and the poor quality of the studies, we intend that
this reviewgives researchersand clinicians more information
of the real clinical usages of moxibustion, and thus it could
be extended over a wide ﬁeld of disorder for practice andEvidence-Based Complementary and Alternative Medicine 17
research. Of course, more speciﬁc and rigorous trials with
l a r g es a m p l es i z e sa r en e e d e dt oe v a l u a t et h ee ﬀectiveness of
moxibustion for each disease.
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